Stories from people navigating Prostate Cancer — diagnosis, treatment, caregiving, and the ordinary days in between.
7 stories
Oncology
The FDA has expanded talazoparib plus enzalutamide to selected adults with HRR-mutated metastatic castration-sensitive prostate cancer. Treatment requires mutation confirmation with an FDA-authorized test.
Rayan Salih · November 10, 2026 · 7 min
Oncology
The FDA approved talazoparib plus enzalutamide for adults with HRR-mutated metastatic prostate cancer that remains naïve or sensitive to androgen-pathway modulation. An FDA-authorized test must confirm eligibility.
Dr. Abu Bakar · 7 min read
Oncology
The FDA has moved lutetium Lu-177 vipivotide tetraxetan into PSMA-positive metastatic hormone-sensitive prostate cancer when combined with an androgen receptor pathway inhibitor.
Dr. Abu Bakar · 7 min read
Oncology
From Late to Early Intervention: Advanced Prostate Cancer Treatment.
Rayan Salih · 9 min read
Oncology
The Food and Drug Administration has approved the use of Pylarify TruVu, which is an updated version of
Dr. Abu Bakar · 8 min read
Clinical Briefs
Screening for prostate cancer has become routine, but guidelines for screening are evolving.
Dr. Abu Bakar · 12 min read
Oncology
A model for predicting the presence of clinically significant prostate cancer (csPCa) using imaging, clinical and patient specific
Dr. Abu Bakar · 8 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.